Skip to main content
Premium Trial:

Request an Annual Quote

Penn to Award More Than $250K in Interdisciplinary Genomics Grants

NEW YORK (GenomeWeb News) – The University of Pennsylvania plans to support novel interdisciplinary genomics research by faculty members with up to $270,000 for two-year programs, the university said today. 
The Penn Genome Frontiers Institute said the “seed grants” will fund new programs in areas such as complex system-level genomics; computational modeling and analysis; single-cell and live cell genomics; sensing technology and high-throughput technology development; and genomics applications to translational research.
PGFI will place emphasis on programs such as epilepsy research that combines engineering intervention, model organisms, neuro-anatomy and molecular physiology; organismal development involving cell biology, genetics, biomechanics, mathematical modeling, and evolution; and cell biology programs that combine novel optical imaging, microfluidics, genetics, biomaterials, and mathematical modeling.
The first phase of the grant programs will award researchers $20,000 for six months in order to plan for the Phase II grant, which could provide up to $250,000 over two years.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.